Early Study Hints at Safety Edge With Apixaban in TAVR Patients With AF

The data add to the debate over the optimal antithrombotic strategy for post-TAVR patients, an issue currently awaiting a “wealth of information” from a “potpourri of [ongoing] trials.”
Heartwire from Medscape